Table II.

Lymphocyte CD20 before and after treatment in three groups of patients (%).

Groups	Before treatment	After treatment	t-test	P-value
Rituximab group (n=79)	28.6±3.5	17.4±3.3	20.69	<0.001
Cyclophosphamide group (n=86)	27.8±3.9	22.3±2.8a	10.62	<0.001
Combined therapy group (n=84)	28.1±3.7	11.7±2.3a,b	34.5	<0.001
F-value	0.954	50.71
P-value	0.387	<0.001

^aP<0.05, compared with rituximab group

^bP<0.05, compared with cyclophosphamide group.